<DOC>
	<DOC>NCT01023516</DOC>
	<brief_summary>The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD</brief_summary>
	<brief_title>Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Diagnosis of COPD with symptoms over 1 year FEV1/FVC &lt; 70% and FEV1 &gt;= 30 and &lt; 80 % of predicted postbronchodilator Symptomatic COPD for a total of 7 days in the two weeks prior to randomisation At least 1 COPD exacerbation from 4 weeks to 12 months before the screening visit Past history or current evidence of clinically significant heart disease Current diagnosis of asthma Patients who require long term oxygen therapy Worsening of COPD requiring treatment with antibiotics, an increase in inhaled steroid dose and/or oral steroids within 4 weeks of study visit 1b</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Chronic</keyword>
	<keyword>obstructive</keyword>
	<keyword>pulmonary</keyword>
	<keyword>lung</keyword>
	<keyword>respiratory disease</keyword>
	<keyword>efficacy</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>COPD</keyword>
	<keyword>FEV1</keyword>
	<keyword>St Georges Respiratory Questionnaire</keyword>
</DOC>